| Literature DB >> 29558982 |
Tara McCrimmon1,2, Susan Witte1,2, Gaukhar Mergenova1, Assel Terlikbayeva1, Sholpan Primbetova1, Azamat Kuskulov1, Scarlett L Bellamy3, Nabila El-Bassel4,5.
Abstract
BACKGROUND: Among women at high risk for HIV and other sexually transmitted diseases (STIs), gender and economic issues limit the impact of behavioral prevention strategies. Women in Kazakhstan with dual risks of sex trading and drug use face elevated risk for HIV and STIs and may benefit from an economic empowerment intervention which combines HIV-risk reduction (HIVRR) education with financial skills-building and asset-building to promote reduced reliance on sex trading for income. METHODS/Entities:
Keywords: Drug use; HIV; Microfinance; STI; Women
Mesh:
Year: 2018 PMID: 29558982 PMCID: PMC5859522 DOI: 10.1186/s13063-018-2566-y
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Theoretical framework
Assessment variables
| Measurement | Timepointa | ||||
|---|---|---|---|---|---|
| Moderators | B | M6 | M9 | M15 | |
| Age, income, education, marital status, experience of sex work, trauma | Sociodemographic Questionnaire | X | X | X | X |
| Substance abuse and criminal justice history | Modified Risk Behavior Assessment (RBA) [ | X | X | X | X |
| Mental health status | BSI [ | X | X | X | X |
| Partner violence history (paying and intimate) | Revised Conflict Tactics Scale [ | X | X | X | X |
| Number and type of sexual partners (past year) | Modified RBA [ | X | X | X | X |
| Perceived stigma | Modified Sex Worker Stigma (SWS) Index [ | X | X | X | X |
| Mediators | B | M6 | M9 | M15 | |
| HIV/STI knowledge | HIV/STI knowledge [ | X | X | X | X |
| Condom use self-efficacy | Condom Use Self-Efficacy Scale [ | X | X | X | X |
| Condom use outcome expectancies | Condom Barriers Scale [ | X | X | X | X |
| Condom negotiation self-efficacy | Condom Negotiation Self Efficacy Scale [ | X | X | X | X |
| Sexual communication skills | Sexual Communication Scale [ | X | X | X | X |
| Social support | MSPSS [ | X | X | X | X |
| Current partner violence (paying and intimate) | Revised Conflict Tactics scale [ | X | X | X | X |
| Access to services | RBA Services [ | X | X | X | X |
| bFinancial literacy | Financial literacy knowledge [ | X | X | X | X |
| bSavings deposits | Bank Statements | X | X | X | |
| bVocational training sessions attended | Attendance/process | X | X | X | |
| Outcomes | B | M6 | M9 | M15 | |
| STI (gonorrhea, syphilis, trichomoniasis, chlamydia, | Laboratory assays (see Table | X | X | X | |
| Sexual behavioral risk: number and % of unprotected sexual acts | Modified RBA [ | X | X | X | X |
| Number and % shared injection acts, other drug use | Modified RBA [ | X | X | X | X |
| Proportion of income from sex work, savings, debt | Economic Indicators Questionnaire | X | X | X | X |
| Cost of staff time, supplies, overhead for HIVRR and for MF | Project records; Administration review | Ongoing | |||
aB baseline (prior to randomization or intervention); M6 month-6 follow-up, M9 month-9 follow-up, M15 month-15 follow-up
bUniquely associated with asset theory and the HIVRR+MF arm
HCV hepatitis C virus, HIV human immunodeficiency virus, HIVRR HIV relative risk, MF microfinance, STI sexually transmitted disease
Fig. 2Consolidated Standards of Reporting Trials (CONSORT) flow diagram
Fig. 3Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule
Biotesting systems used
| Infection | Testing specimen | Test system used | Sensitivity (95% CIa) | Specificity (95% CIa) |
|---|---|---|---|---|
| HIV | Finger stick (whole blood sample) | Alere Determine™ HIV-1/2 Ag/Ab Combo rapid test system [ | 99.9% (99.4–100.0%) | 99.8% (99.5–99.9%) |
| Hepatitis C (HCV) | Dried blood spot | Murex anti-HCV (version 4.0) [ | 100% (94.79-100%) | 99.88% (99.77–99.94%) |
| Syphilis | Dried blood spot | Murex ICE Syphilis [ | 100% (99.1–100%) | 100% (99.2–100%) |
| Gonorrhea | Vaginal specimen | AmpliSense | N/Ab | N/Ab |
| Trichomoniasis | Vaginal specimen | AmpliSense | N/Ab | N/Ab |
| Chlamydia | Vaginal specimen | AmpliSense | 100% (73.3–100%) | 100% (98.1–- 100%) |
|
| Vaginal specimen | AmpliSense | 76.5% (50.1–93.0%) | 100% (98.1–100%) |
aCI confidence interval
bN/A estimates are not available for vaginal specimen samples